CMS Announces Increased Reimbursement for Monoclonal Antibody Administration The Centers for Medicare & Medicaid Services (CMS) has increased the Medicare payment rate for the administration of monoclonal antibodies for the treatment of beneficiaries with COVID-19, effective May 6. In addition, CMS has established a higher reimbursement rate for monoclonal antibody administration performed in a beneficiary’s permanent residence...
This content is restricted to members.